Positron emission tomography for lymphoma staging: Tissue remains the issue [4]

Journal of the National Cancer Institute

Volumn 97, Issue 8, 2005, Pages 611-613

  Srinivasan, Ramaprasad ^a,b   Filie, Armando ^b   Reynolds, James ^c   Chang, Richard ^c   Chow, Catherine ^c   Schrump, David S ^b   Takahashi, Yoshiyuki ^a   Suffredini, Anthony F ^c   Childs, Richard W ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; FLUORODEOXYGLUCOSE F 18; FOLINIC ACID; METHOTREXATE; PREDNISONE; VINCRISTINE; ANTINEOPLASTIC AGENT;

ADOLESCENT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ASPIRATION BIOPSY; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER STAGING; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; DIAGNOSTIC PROCEDURE; DIAGNOSTIC VALUE; FEMALE; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; LETTER; LUNG BIOPSY; LYMPHADENOPATHY; NONHODGKIN LYMPHOMA; PLEURA EFFUSION; PLEURODESIS; PNEUMOTHORAX; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; THORACOSCOPY; B CELL LYMPHOMA; LYMPHOSARCOMA; PATHOLOGY; PREDICTION AND FORECASTING; RADIOGRAPHY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; LYMPHOMA, B-CELL; LYMPHOMA, DIFFUSE; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 17144407622     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/dji110     Document Type: Letter

References (7)

1. Burton C, Ell P, Linch D. The role of PET imaging in lymphoma. Br J Haematol 2004;126:772-84.
2. 18F]fluoro-D-glucosepositronemission tomography for predicting the clinical outcome of previously treated non-Hodgkin's lymphoma patients. Mol Imaging Biol 2003;5:232-9.
3. Friedberg JW, Chengazi V. PET scans in the staging of lymphoma: current status. Oncologist 2003;8:438-47.
4. Friedberg JW, Fischman A, Neuberg D, Kim H, Takvorian T, Ng AK, et al. FDG-PET is superior to gallium scintigraphy in staging and more sensitive in the follow-up of patients with de novo Hodgkin lymphoma: a blinded comparison. Leuk Lymphoma 2004;45:85-92.
5. 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma. Haematologica 2000;85:613-8.
6. Barrington SF, O'Doherty MJ. Limitations of PET for imaging lymphoma. Eur J Nucl Med Mol Imaging 2003;30 Suppl 1:S117-27.
7. 18F-fluorodeoxyglucose positron emission tomography. AJR Am J Roentgenol 1997;168:359-60.